source
- Taiho and Cullinan's zipalertinib clears Phase 3 trial in EGFR-mutated lung cancerTaiho Oncology and Cullinan Therapeutics announced that their oral EGFR inhibitor zipalertinib successfully completed a registrational Phase 3 study in patients with a specific genetic form of lung…
- European regulators withdraw Amgen's Tavneos over questionable dataEuropean regulators announced they are pulling Amgen's rare disease drug Tavneos from the European market after reviewing data they deemed incorrect and misleading. The authorities said the data s…